Form 8-K - Current report:
SEC Accession No. 0001104659-24-092644
Filing Date
2024-08-26
Accepted
2024-08-26 08:22:48
Documents
15
Period of Report
2024-08-22
Items
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2422579d1_8k.htm   iXBRL 8-K 34455
2 EXHIBIT 3.1 tm2422579d1_ex3-1.htm EX-3.1 1266
6 GRAPHIC tm2422579d1_ex3-1img001.jpg GRAPHIC 495946
  Complete submission text file 0001104659-24-092644.txt   897492

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA syn-20240822.xsd EX-101.SCH 3042
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE syn-20240822_lab.xml EX-101.LAB 34240
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE syn-20240822_pre.xml EX-101.PRE 22378
17 EXTRACTED XBRL INSTANCE DOCUMENT tm2422579d1_8k_htm.xml XML 3808
Mailing Address 9605 MEDICAL CENTER DRIVE SUITE 270 ROCKVILLE MD 20850
Business Address 9605 MEDICAL CENTER DRIVE SUITE 270 ROCKVILLE MD 20850 (734) 332-7800
Theriva Biologics, Inc. (Filer) CIK: 0000894158 (see all company filings)

EIN.: 133808303 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-12584 | Film No.: 241237845
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)